Breast Cancer Clinical Trial
Official title:
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: - the recommended dose for Phase 2 - to evaluate the safety and tolerability of the combination therapy - to determine the pharmacokinetics of TNG260 - to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Status | Recruiting |
Enrollment | 126 |
Est. completion date | June 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Is =18 years of age at the time of signature of the main study ICF. - Has ECOG performance status of 0 or 1. - Has measurable disease based on RECIST v1.1. - All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method - Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor. - Adequate organ function/reserve per local labs - Adequate liver function per local labs - Adequate renal function per local labs - Negative serum pregnancy test result at screening - Written informed consent must be obtained according to local guidelines Exclusion Criteria: - Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients - Uncontrolled intercurrent illness that will limit compliance with the study requirements - Active infection requiring systemic therapy - Currently participating in or has planned participation in a study of another investigational agent or device - Impairment of GI function or disease that may significantly alter the absorption of oral TNG260 - Active prior or concurrent malignancy. - Central nervous system metastases associated with progressive neurological symptoms - Current active liver disease from any cause - Clinically relevant cardiovascular disease - A female patient who is pregnant or lactating |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | SCRI at HealthOne | Denver | Colorado |
United States | Henry Ford Health System | Detroit | Michigan |
United States | NEXT Oncology Virginia | Fairfax | Virginia |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Sarah Cannon Tennessee Oncology | Nashville | Tennessee |
United States | New York University Langone Health | New York | New York |
United States | UCLA Hematology/Oncology | Santa Monica | California |
United States | Florida Cancer Specialists | Sarasota | Florida |
Lead Sponsor | Collaborator |
---|---|
Tango Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the MTD and RP2D(s) (Phase 1 only) | To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab | 42 days | |
Primary | Measure antitumor activity using RECIST 1.1 (Phase 2 only) | To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1 | 12 weeks | |
Secondary | Measure antitumor evidence of TNG260 + pembrolizumab antineoplastic activity by RECIST 1.1 (Phase 1 only) | To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1 | 12 weeks | |
Secondary | Characterize Area Under the Curve (AUC) of TNG260 | Measure the plasma concentration versus time curve (AUC) of TNG260 alone and when administered in combination with pembrolizumab | 37 days | |
Secondary | Characterize the time to achieve Time to Maximal Concentration (Tmax) of TNG260 | To characterize the Tmax by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab | 37 days | |
Secondary | Characterize Maximum Observed Plasma Concentration (Cmax) of TNG260 | To characterize the Cmax by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab | 37 days | |
Secondary | Characterize Terminal Half-life (T1/2) of TNG260 | To characterize the T1/2 by measuring the plasma concentrations versus time of TNG260 alone and when administered in combination with pembrolizumab | 37 days | |
Secondary | Characterize pembrolizumab concentrations when administered with TNG260 | To characterize the pre treatment and trough concentration levels of pembrolizumab when administered in combination with TNG260 | 43 days | |
Secondary | Safety and tolerability of TNG260 by CTCAE 5.0 | To evaluate the safety and tolerability of TNG260 when administered as single agent and in combination with pembrolizumab by measuring the incidence, nature, and severity of AE and SAE graded according to CTCAE v5.0 | 42 days | |
Secondary | To measure changes in histone acetylation when administered with TNG260 | Measure changes in levels of histone acetylation in blood and/or tumor tissue, on study treatment relative to pre-treatment | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |